Using Daratumumab to Treat High-Risk Myeloma Patients

Mar 15, 2022
07:00PM - 08:15PM EDT
Online Event
Overview

Is there a benefit associated with adding daratumumab to backbone myeloma treatment regimens among patients with cytogenetically defined high-risk multiple myeloma (HRMM)? Learn from Dr. Luciano Costa on this subject and come with your questions.

Agenda
07:00 PM
Introduction
Audrey Burton-Bethke
Audrey introduces the agenda of the event and featured speaker Dr. Luciano Costa.
07:05 PM
Presentation
Luciano Costa, MD, PhD
Dr. Costa talks about benefits associated with adding daratumumab to backbone myeloma treatment regimens among patients with cytogenetically defined high-risk multiple myeloma (HRMM).
07:45 PM
Questions and Answers
Audience
Type your questions in the chat and we will answer them!
Speakers & Moderators
Healthtree contact Audrey Burton-Bethke

Audrey Burton-Bethke

Audrey is a content writer and editor for the HealthTree Foundation.

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Healthtree contact Luciano Costa, MD, PhD

Luciano Costa, MD, PhD

Luciano J. Costa, M.D., Ph.D., serves as the Associate Director for Clinical Research at the O’Neal Comprehensive Cancer Center at UAB.

Luciano J. Costa, M.D., Ph.D., serves as the Associate Director for Clinical Research at the O’Neal Comprehensive Cancer Center at UAB. Dr. Costa obtained his M.D. and subsequently Ph.D. from Universidade de Sao Paulo, Brazil. He then trained in hematology and medical oncology at the University of Colorado in Aurora and in blood and marrow transplantation at the Mayo Clinic in Rochester, Minnesota. Prior to joining UAB, Dr. Costa was an Associate Professor of Medicine at the Medical University of South Carolina where he co-chaired the Protocol Review Committee at Hollings Cancer Center. He was recruited to the O’Neal Comprehensive Cancer Center in 2014 as a Senior Clinical Investigator and currently directs the Multiple Myeloma and the Immune Effector Cellular Therapy programs. His primary research focus is the development of new therapies for plasma cell malignancies. Dr. Costa leads several multi-institutional and international projects exploring new cellular and immunotherapies and minimal residual disease in myeloma. He is regarded as an international leader in the field with more than 200 peer-reviewed abstracts and publications in high-impact journals such as Blood, Leukemia, the Journal of Clinical Oncology and The New England Journal of Medicine.